Human VEGF165 Protein, premium grade

分子別名（Synonym）

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）

Human VEGF165, premium grade (VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).

Predicted N-terminus: Ala 27

該產(chǎn)品是在我們嚴(yán)格的質(zhì)量控制體系下生產(chǎn)的，該體系包括一系列全面的測試，包括無菌和內(nèi)毒素測試。在臨床前早期階段，產(chǎn)品性能經(jīng)過仔細(xì)驗(yàn)證和測試，可用于細(xì)胞培養(yǎng)或任何其他應(yīng)用。當(dāng)準(zhǔn)備進(jìn)入后期臨床階段時，我們還提供定制GMP蛋白質(zhì)服務(wù)，以滿足您的需求。我們將與您合作，根據(jù)您的要求定制和開發(fā)GMP級產(chǎn)品，該產(chǎn)品也符合細(xì)胞療法細(xì)胞制造中使用的原材料和輔助材料的要求。

蛋白結(jié)構(gòu)（Molecular Characterization） 

This protein carries no "tag".

The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

內(nèi)毒素（Endotoxin）

Less than 0.01 EU per μg by the LAL method.

宿主蛋白殘留（Host Cell Protein）

<0.5 ng/μg of protein tested by ELISA.

宿主核酸殘留（Host Cell DNA）

<0.02 ng/μg of protein tested by qPCR.

無菌（Sterility）

Negative

支原體（Mycoplasma）

Negative.

純度（Purity）

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

制劑（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重構(gòu)方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存儲（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 24 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景（Background）

VEGF165是VEGF-A最豐富的剪接變體。VEGF165由許多細(xì)胞產(chǎn)生，包括內(nèi)皮細(xì)胞，巨噬細(xì)胞和T細(xì)胞。VEGF165參與血管生成，血管內(nèi)皮細(xì)胞存活，生長，遷移和血管通透性。VEGF基因表達(dá)由缺氧，炎性細(xì)胞因子和癌基因誘導(dǎo)。VEGF165與硫酸乙酰肝素結(jié)合并保留在細(xì)胞表面和細(xì)胞外基質(zhì)中。VEGF165與受體酪氨酸激酶VEGFR1和VEGFR2結(jié)合。VEGF165是唯一與共受體NRP-1和NRP-2結(jié)合的剪接變體，其功能是增強(qiáng)VEGFR2信號傳導(dǎo)。VEGF165與VEGFR1和VEGFR2的結(jié)合導(dǎo)致PI3K/AKT，p38 MAPK，FAK和樁蛋白的激活。VEGF在許多癌癥的腫瘤血管生成中起關(guān)鍵作用。